Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Ryu, Nagata, Kazuyoshi, Fukushima, Masanori, Haraguchi, Masafumi, Miuma, Satoshi, Miyaaki, Hisamitsu, Soyama, Akihiko, Hidaka, Masaaki, Eguchi, Susumu, Shigeno, Masaya, Yamashima, Mio, Yamamichi, Shinobu, Ichikawa, Tatsuki, Kugiyama, Yuki, Yatsuhashi, Hiroshi, Nakao, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834002/
https://www.ncbi.nlm.nih.gov/pubmed/35159095
http://dx.doi.org/10.3390/cancers14030827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834002/
https://www.ncbi.nlm.nih.gov/pubmed/35159095
http://dx.doi.org/10.3390/cancers14030827

Ejemplares similares